Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Neurobiol ; 58(8): 3769-3786, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33826070

ABSTRACT

Correct operation of neuronal networks depends on the interplay between synaptic excitation and inhibition processes leading to a dynamic state termed balanced network. In the spinal cord, balanced network activity is fundamental for the expression of locomotor patterns necessary for rhythmic activation of limb extensor and flexor muscles. After spinal cord lesion, paralysis ensues often followed by spasticity. These conditions imply that, below the damaged site, the state of balanced networks has been disrupted and that restoration might be attempted by modulating the excitability of sublesional spinal neurons. Because of the widespread expression of inhibitory GABAergic neurons in the spinal cord, their role in the early and late phases of spinal cord injury deserves full attention. Thus, an early surge in extracellular GABA might be involved in the onset of spinal shock while a relative deficit of GABAergic mechanisms may be a contributor to spasticity. We discuss the role of GABA A receptors at synaptic and extrasynaptic level to modulate network excitability and to offer a pharmacological target for symptom control. In particular, it is proposed that activation of GABA A receptors with synthetic GABA agonists may downregulate motoneuron hyperexcitability (due to enhanced persistent ionic currents) and, therefore, diminish spasticity. This approach might constitute a complementary strategy to regulate network excitability after injury so that reconstruction of damaged spinal networks with new materials or cell transplants might proceed more successfully.


Subject(s)
Excitatory Postsynaptic Potentials/physiology , Inhibitory Postsynaptic Potentials/physiology , Nerve Net/metabolism , Receptors, GABA-A/metabolism , Spinal Cord Injuries/metabolism , Spinal Cord/metabolism , Animals , GABAergic Neurons/physiology , Humans , Motor Neurons/metabolism , Motor Neurons/pathology , Nerve Net/pathology , Spinal Cord/pathology , Spinal Cord Injuries/physiopathology
2.
Synapse ; 71(12)2017 12.
Article in English | MEDLINE | ID: mdl-28873252

ABSTRACT

Acetazolamide (AZ), a molecule frequently used to treat different neurological syndromes, is an inhibitor of the carbonic anhydrase (CA), an enzyme that regulates pH inside and outside cells. We combined fluorescent FM styryl dyes and electrophysiological techniques at ex vivo levator auris longus neuromuscular junctions (NMJs) from mice to investigate the modulation of synaptic transmission and vesicle recycling by AZ. Transmitter release was minimally affected by AZ, as evidenced by evoked and spontaneous end-plate potential measurements. However, optical evaluation with FM-styryl dyes of vesicle exocytosis elicited by 50 Hz stimuli showed a strong reduction in fluorescence loss in AZ treated NMJ, an effect that was abolished by bathing the NMJ in Hepes. The remaining dye was quenched by bromophenol, a small molecule capable of diffusing inside vesicles. Furthermore, in transgenic mice expressing Synaptophysin-pHluorin (SypHy), the fluorescence responses of motor nerve terminals to a 50 Hz train of stimuli was decrease to a 50% of controls in the presence of AZ. Immunohistochemistry experiments to evaluate the state of the Myosin light chain kinase (MLCK), an enzyme involved in vesicle recycling, demonstrated that MLCK phosphorylation was much stronger in the presence than AZ than in its absence in 50 Hz stimulated NMJs. We postulate that AZ, via cytosol acidification and activation of MLCK, shifts synaptic vesicle recycling to a fast (kiss-and-run) mode, which changes synaptic performance. These changes may contribute to the therapeutic action reported in many neurological syndromes like ataxia, epilepsy, and migraine.


Subject(s)
Acetazolamide/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Neuromuscular Agents/pharmacology , Neuromuscular Junction/drug effects , Synaptic Vesicles/drug effects , Animals , Cardiac Myosins/metabolism , Cytosol/drug effects , Cytosol/metabolism , Exocytosis/drug effects , Exocytosis/physiology , Hydrogen-Ion Concentration , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice, Inbred C57BL , Mice, Transgenic , Myosin Light Chains/metabolism , Myosin-Light-Chain Kinase/metabolism , Neuromuscular Junction/cytology , Neuromuscular Junction/metabolism , Phosphorylation/drug effects , Synaptic Vesicles/metabolism
3.
Biochem Biophys Res Commun ; 386(2): 338-44, 2009 Aug 21.
Article in English | MEDLINE | ID: mdl-19523446

ABSTRACT

Since an increased serum unconjugated bilirubin (UCB) level has been proposed as an independent protective factor against atherosclerotic disease, we investigated the molecular events at the basis of this effect. HUVEC and H5V cells were treated with TNFalpha and UCB and the effects assessed on E-selectin, VCAM-1 and ICAM-1. In HUVEC cells, UCB blunted the TNFalpha-induced gene upregulation of E-selectin VCAM-1 and ICAM-1. The same pattern was observed in H5V cells except for ICAM-1. UCB also inhibited the PMN endothelial adhesion in HUVEC H5V cells. Western blot and FACS analysis confirmed that UCB prevented TNFalpha-induced over-expression of adhesion molecules proteins in H5V cells. These data contribute to further explain the protective effect of bilirubin against development of atherosclerosis.


Subject(s)
Bilirubin/metabolism , E-Selectin/biosynthesis , Intercellular Adhesion Molecule-1/biosynthesis , Neutrophils/physiology , Vascular Cell Adhesion Molecule-1/biosynthesis , Bilirubin/pharmacology , Cell Adhesion/drug effects , Cell Line , E-Selectin/genetics , Humans , Intercellular Adhesion Molecule-1/genetics , Neutrophils/drug effects , Neutrophils/metabolism , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Umbilical Cord/cytology , Umbilical Cord/drug effects , Umbilical Cord/metabolism , Up-Regulation/drug effects , Vascular Cell Adhesion Molecule-1/genetics
4.
Biosci Trends ; 3(4): 151-7, 2009 Aug.
Article in English | MEDLINE | ID: mdl-20103840

ABSTRACT

We have recently demonstrated that unconjugated bilirubin (UCB) limits the overexpression of adhesion molecules and inhibits the PMN endothelial adhesion induced by the pro-inflammatory cytokine TNFalpha. To understand the molecular events involved we investigated whether the inhibitory effect is determined by a direct influence of UCB on different nuclear pathways. Co-treatment of cells with UCB, TNFalpha, and pyrridoline dithiocarbamate (PDTC), a NF-kappaB inhibitor, additively enhanced the inhibitory effect of UCB. UCB prevented the nuclear translocation of NF-kappaB induced by TNFalpha. The failure of UCB to alter TNFalpha-induced phosphorylation of cAMP-response element-binding protein (CREB) suggested that the CREB pathway is not involved in the UCB inhibition and that UCB blunting effect on the overexpression of adhesion molecules occurs via inhibition of the NF-kappaB transduction pathway. Collectively these data may contribute to explain the protective effect of bilirubin against development of atherosclerosis.


Subject(s)
Bilirubin/pharmacology , Cell Adhesion Molecules/metabolism , NF-kappa B/metabolism , Signal Transduction/drug effects , Active Transport, Cell Nucleus/drug effects , Analysis of Variance , Animals , Atherosclerosis/prevention & control , Bilirubin/metabolism , Blotting, Western , CREB-Binding Protein/metabolism , Cell Line , Mice , NF-kappa B/antagonists & inhibitors , Phosphorylation , Proline/analogs & derivatives , Proline/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Thiocarbamates/pharmacology , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...